Otonomy, Inc.

Mimetogen Pharmaceuticals, Inc

Other

Horacio Url Saragovi

Horacio Uri Saragovi

Aoa Dx

Saragovi, Horacio Uri

Fabrice Piu

Garth Cumberlidge

Karen Meerovitch

Neil R Cashman

Teresa Lama

Wenyong Tong

Hinyu Nedev

Véronique Guillemard

KristenAnn Black

Alan Foster

The present invention provides methods and compositions related to multivalent carbohydrate antigen structures comprising cancer or infection associated ganglioside carbohydrate antigens. Said carbohydrate structures may be used to induce immunity against said carbohydrate antigens. In some embodiments, carbohydrate structures may be administered to a subject thereby inducing immunity in the subject, for example, the administration of a vaccine comprising said carbohydrate structure. Also provided are methods to induce an immune response in a subject in need thereof by administering said carbohydrate structure. Further provided are methods of producing an antibody or TCR that bind said carbohydrate antigens.

Carbohydrate structures and uses thereof

Disclosed herein are methods, compositions, vectors, and kits comprising an antagonist of a truncated TrkC or a truncated TrkB. Also described herein are methods of treating and/or preventing an otic disease or condition associated with an elevated expression level of a truncated TrkC or truncated TrkB isoform.

Treatment using truncated Trk B and Trk C antagonists

It is provided a multivalent ganglioside carbohydrate as a therapeutic cancer vaccine. The GD2 and GD3 carbohydrate conjugated disclosed are linked by a spacer to form a multimer which conserves the native structural feature of naturally occurring GD2 or GD3, the tetramer being immunogenic and elicits cytotoxic anti-gangliosides humoral and cellular responses in vivo.

Anti-ganglioside compound for targeting cancer and generating antibodies

The present invention relates to methods of treating dry eye using &#x3b2;-turn peptidomimetic cyclic compounds or derivatives thereof. The &#x3b2;-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs that treat dry eye.

Beta-turn peptidomimetic cyclic compounds for treating dry eye

Novel p75 receptor antagonist compounds and compositions and uses thereof for the prevention and treatment of p75-associated disorders, such as neurodegenerative diseases, are described.

Inhibitors of p75 receptor and their uses

There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.

Agonistic antibodies to TrkC receptors and uses thereof

The present invention relates to methods of treating retinitis pigmentosa using &#x3b2;-turn peptidomimetic cyclic compounds or derivatives thereof. The &#x3b2;-turn peptidomimetic cyclic compounds can be used alone, in combination and/or in conjunction with one or more other compounds, molecules or drugs useful in treating retinitis pigmentosa.

Growing community of inventors

Montreal, Canada

Horacio Uri Saragovi